Market Research Report

Global Metabolic Disorder Therapeutics Market Report By Product (Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, And Others), Disease (Diabetes, Obesity, Hypercholesterolemia, And Lysosomal Storage Diseases), And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2028

ID:VMR11210578
March 2022
Report Formats: Report Formats
As per this study the Global Metabolic Disorder Therapeutics Market was valued USD XX MN (by revenue) in 2021 and is anticipated to reach USD XX MN by 2028 with a CAGR of XX%.

Metabolism is a process in a digestive system where the food is broken down into glucose, amino acids, and fatty acids. A metabolic disorder is a condition when the body is unable to process metabolism and it can be caused due to unhealthy eating lifestyle. A metabolic disorder is either inherited genetically or acquired during the lifetime. Some metabolic disorders show mild symptoms that can be managed with slight medication whereas high symptoms such as breathing problems, organ failures, diabetes and others can be life-threatening. The treatment for this disorder can be done by enzyme replacement therapy, drug therapy, and others through oral and other administrations.
 
Market Dynamics
 
The rising incidences of obesity, diabetes and high cholesterol among the population is fueling the global metabolism market growth. Also, an increasing prevalence of unhealthy lifestyle diseases which leads to various digestive issues is also stimulating the market growth. On the flip side, the high cost of treatment for metabolic disorder is expected to restrain market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of metabolic disorder therapeutics.
 
Market Segmentation
 
The broad metabolic disorder therapeutics market has been sub-grouped into product and disease. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Product
  • Metachromatic Leukodystrophy
  • Globoid Leukodystrophy
  • Hepatic Encephalopathy
  • Others
 
By Disease
  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal Storage Diseases
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for metabolic disorder therapeutics in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Global Metabolic Disorder Therapeutics Market Share by Region (Representative Graph)

Global Metabolic Disorder Therapeutics Market Share

The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Metabolic Disorder Therapeutics market include AbbVie Inc., Actelion Pharmaceuticals Ltd., AstraZeneca, Biocon, Boehringer Ingelheim, CymaBay Therapeutics, Eli Lilly and Company, Merck KgaA, Novo Nordisk, and Sanofi. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . METABOLIC DISORDER THERAPEUTICS – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 Market Attractiveness Analysis By Product
           3.7.2 Market Attractiveness Analysis By Disease
           3.7.3 Market Attractiveness Analysis By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic 
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY PRODUCT
       6.1 Overview by Product
       6.2 Historical and Forecast Data
       6.3 Analysis by Product
       6.4 Metachromatic Leukodystrophy Historic and Forecast Sales by Regions
       6.6 Globoid Leukodystrophy Historic and Forecast Sales by Regions
       6.5 Hepatic Encephalopathy Historic and Forecast Sales by Regions
       6.7 Others Historic and Forecast Sales by Regions
 
7 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY DISEASE
       7.1 Overview by Disease
       7.2 Historical and Forecast Data
       7.3 Analysis by Disease
       7.4 Diabetes Historic and Forecast Sales by Regions
       7.5 Obesity Historic and Forecast Sales by Regions
       7.6 Hypercholesterolemia Historic and Forecast Sales by Regions
       7.7 Lysosomal Storage Diseases Historic and Forecast Sales by Regions
 
8 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY
       8.1. Regional Outlook
       8.2. Introduction
       8.3. North America Sales Analysis
           8.3.1. Overview, Historic and Forecast Sales Analysis
           8.3.2. North America By Segment Sales Analysis
           8.3.3. North America By Country Sales Analysis
           8.3.4. United State Sales Analysis
           8.3.5. Canada Sales Analysis
           8.3.6. Mexico Sales Analysis
       8.4. Europe Sales Analysis
           8.4.1. Overview, Historic and Forecast Sales Analysis
           8.4.2. Europe by Segment Sales Analysis
           8.4.3. Europe by Country Sales Analysis
           8.4.4. United Kingdom Sales Analysis
           8.4.5. France Sales Analysis
           8.4.6. Germany Sales Analysis
           8.4.7. Italy Sales Analysis
           8.4.8. Russia Sales Analysis
           8.4.9. Rest Of Europe Sales Analysis
       8.5. Asia Pacific Sales Analysis
           8.5.1. Overview, Historic and Forecast Sales Analysis
           8.5.2. Asia Pacific by Segment Sales Analysis
           8.5.3. Asia Pacific by Country Sales Analysis
           8.5.4. China Sales Analysis
           8.5.5. India Sales Analysis
           8.5.6. Japan Sales Analysis
           8.5.7. South Korea Sales Analysis
           8.5.8. Australia Sales Analysis
           8.5.9. Rest Of Asia Pacific Sales Analysis
       8.6. Latin America Sales Analysis
           8.6.1. Overview, Historic and Forecast Sales Analysis
           8.6.2. Latin America by Segment Sales Analysis
           8.6.3. Latin America by Country Sales Analysis
           8.6.4. Brazil Sales Analysis
           8.6.5. Argentina Sales Analysis
           8.6.6. Peru Sales Analysis
           8.6.7. Chile Sales Analysis
           8.6.8. Rest of Latin America Sales Analysis
       8.7. Middle East & Africa Sales Analysis
           8.7.1. Overview, Historic and Forecast Sales Analysis
           8.7.2. Middle East & Africa by Segment Sales Analysis
           8.7.3. Middle East & Africa by Country Sales Analysis
           8.7.4. Saudi Arabia Sales Analysis
           8.7.5. UAE Sales Analysis
           8.7.6. Israel Sales Analysis
           8.7.7. South Africa Sales Analysis
           8.7.8. Rest Of Middle East And Africa Sales Analysis
 
9 . COMPETITIVE LANDSCAPE OF THE METABOLIC DISORDER THERAPEUTICS COMPANIES
       9.1. Metabolic Disorder Therapeutics Market Competition
       9.2. Partnership/Collaboration/Agreement
       9.3. Merger And Acquisitions
       9.4. New Product Launch
       9.5. Other Developments
 
10 . COMPANY PROFILES OF METABOLIC DISORDER THERAPEUTICS INDUSTRY
       10.1. Top Companies Market Share Analysis
       10.2. Market Concentration Rate
       10.3. AbbVie Inc.
           10.3.1. Company Overview
           10.3.2. Company Revenue
           10.3.3. Products
           10.3.4. Recent Developments
       10.4. Actelion Pharmaceuticals Ltd.
           10.4.1. Company Overview
           10.4.2. Company Revenue
           10.4.3. Products
           10.4.4. Recent Developments
       10.5. AstraZeneca
           10.5.1. Company Overview
           10.5.2. Company Revenue
           10.5.3. Products
           10.5.4. Recent Developments
       10.6. Biocon
           10.6.1. Company Overview
           10.6.2. Company Revenue
           10.6.3. Products
           10.6.4. Recent Developments
       10.7. Boehringer Ingelheim
           10.7.1. Company Overview
           10.7.2. Company Revenue
           10.7.3. Products
           10.7.4. Recent Developments
       10.8. CymaBay Therapeutics
           10.8.1. Company Overview
           10.8.2. Company Revenue
           10.8.3. Products
           10.8.4. Recent Developments
       10.9. Eli Lilly and Company
           10.9.1. Company Overview
           10.9.2. Company Revenue
           10.9.3. Products
           10.9.4. Recent Developments
       10.10. Merck KgaA
           10.10.1. Company Overview
           10.10.2. Company Revenue
           10.10.3. Products
           10.10.4. Recent Developments
       10.11. Novo Nordisk
           10.11.1. Company Overview
           10.11.2. Company Revenue
           10.11.3. Products
           10.11.4. Recent Developments
       10.12. Sanofi
           10.12.1. Company Overview
           10.12.2. Company Revenue
           10.12.3. Products
           10.12.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
 LIST OF TABLES
 

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  COVID-19 Impact Analysis by Production, Import, Export and Demand
  •  Pre V/S Post COVID-19
  •  Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  •  COVID-19: Micro and Macro Factor Analysis
  •  Analysis by Product (USD MN)
  •  Metachromatic Leukodystrophy Market Sales by Geography (USD MN)
  •  Globoid Leukodystrophy Market Sales by Geography (USD MN)
  •  Hepatic Encephalopathy Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis Market by Disease (USD MN)
  •  Diabetes Market Sales by Geography (USD MN)
  •  Obesity Market Sales by Geography (USD MN)
  •  Hypercholesterolemia Market Sales by Geography (USD MN)
  •  Lysosomal Storage Diseases Market Sales by Geography (USD MN)
  •  Global Metabolic Disorder Therapeutics Market Sales by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisition
 
 LIST OF FIGURES
 
  •  Research Scope of Metabolic Disorder Therapeutics Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Metabolic Disorder Therapeutics Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Product
  •  Market Attractiveness Analysis by Disease
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Product (USD MN)
  •  Metachromatic Leukodystrophy Market Sales by Geography (USD MN)
  •  Globoid Leukodystrophy Market Sales by Geography (USD MN)
  •  Hepatic Encephalopathy Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Disease (USD MN)
  •  Diabetes Market Sales by Geography (USD MN)
  •  Obesity Market Sales by Geography (USD MN)
  •  Hypercholesterolemia Market Sales by Geography (USD MN)
  •  Lysosomal Storage Diseases Market Sales by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Top Companies Market Share Analysis
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials